New hope for lung cancer: experimental drug HC010 enters phase 2 trial
NCT ID NCT07169552
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a new drug called HC010 in 50 people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). The goal is to see if the drug can shrink tumors and how safe it is. Participants receive HC010 as their first treatment, and researchers will monitor their health and cancer response over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.